EN
Statement
Statement
We have recently noticed that some companies and individuals illegally forged and used authorization documents from Sinovac Biotech Co., Ltd. (“Sinovac Beijing”) or Sinovac Life Sciences Co., Ltd. (“Sinovac Life Sciences”), two subsidiaries of Sinovac Biotech Ltd. (“Sinovac”), to hold out that Sinovac Beijing or Sinovac Life Sciences has authorized them to act as the distributor to distribute the Covid-19 vaccine CoronaVac® and the other vaccine products in the markets outside China.
We wish to clarify that:
(i) the Covid-19 vaccine CoronaVac® is developed, manufactured and distributed by Sinovac Life Sciences;
(ii) Sinovac Beijing is not engaged in distribution of the Covid-19 vaccine CoronaVac® outside China; and
(ii) neither Sinovac nor any of its subsidiaries has ever signed any authorization letter or similar documents for any company or individual within China to authorize them to distribute the Covid-19 vaccine CoronaVac® outside China.
We hereby reiterate that, without signing written contracts with us, no entity or individual may hold out that it is or is authorized to be engaged in sale, distribution or other marketing or promotion activities related to any of Sinovac’s vaccine products.
Concerning the illegal activities of document forging and fraudulence as mentioned, we reserve all the rights to take actions, including legal actions, to seek remedies and pursue liabilities.
Sinovac Biotech Ltd.
28 January 2021
About SINOVAC
Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission of "supply vaccines to eliminate human diseases", the company specializes in the research, development, manufacturing and commercialization of vaccines and related biological products that protect against human infectious diseases.
The company's diversified portfolio includes vaccines for influenza, viral hepatitis, varicella, Hand-Foot-Mouth disease (HFMD), poliomyelitis, pneumococcal disease, etc., of which 3 vaccines have been prequalified by WHO, including inactivated hepatitis A vaccine Healive®, Sabin-strain inactivated polio vaccine (sIPV), and varicella vaccine.
SINOVAC has a leading edge in developing vaccines to combat infectious disease outbreaks and was among the first to initiate R&D during major public health emergencies, including SARS, H5N1, H1N1, and COVID-19. The company developed the world's first inactivated SARS vaccine (Phase I completed), China's first H5N1 influenza vaccine (Paneflu®), the world's first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the most widely used inactivated COVID-19 vaccine globally.
Beyond its marketed portfolio, the company is advancing a robust pipeline that includes combination vaccines,recombinant protein vaccines and next-generation platforms such as mRNA technologies and antibodies.
With a long-standing commitment to innovation and global health, SINOVAC is expanding its global footprint by strengthening partnerships with research institutions, international organizations, and local partners. Through broader market presence, technological cooperation, and localized production, the company aims to accelerate vaccine development and supply, enhance regional access to high-quality products, and better address unmet medical needs while improving preparedness for future pandemics.
For more information, please see the Company’s website at www.sinovac.com.